Amiko Digital Health has announced that Portuguese health care group Luz Saúde has signed an agreement for the use of Amiko’s Respiro inhaler monitoring platform for asthma and COPD management.
Hospital da Luz Learning Health Director Francisca Leite said, “Amiko has a great product that will completely change the way asthma and COPD patients and their health providers can improve the efficacy of the treatment. Using Amiko’s solution I am certain that respiratory patients will feel an important improvement in their health status.”
Amiko CEO Duilio Macchi said, “Our partnership with Luz Saúde is a testament to the unique flexibility of Respiro to effectively integrate into drastically different healthcare structures and deliver system-wide value. The unique capabilities of our sensor technology for inhalers address a fundamental unmet need in respiratory care – the sub-optimal performance of respiratory therapies in the real world. We are thrilled to deliver Respiro with a leading European healthcare network that is dedicated to innovation and upgrade their standards of care using connected technologies.”
Read the Amiko Digital Health press release.
